The House Energy and Commerce (E&C) Committee released an updated draft of its 21st Century Cures Act, reintroducing a provision that would extend market exclusivity for drugs modified to treat rare diseases. House lawmakers agreed to extend drug exclusivity perks for manufacturers on their products by six months if they …